MLD-41

Revision as of 19:45, 27 September 2011 by WikiBot (talk | contribs) (Protected "MLD-41": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
MLD-41
File:MLD-41.svg
Clinical data
SynonymsMLD-41, N1-Methyl-Lysergic Acid Diethylamide
Routes of
administration
Oral
Pharmacokinetic data
Metabolismhepatic
Excretionrenal
Identifiers
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H27N3O2
Molar mass337.47 g/mol

N1-Methyl-Lysergic Acid Diethylamide (MLD-41, 9,10-didehydro-N,N-diethyl-1,6-dimethyl-ergoline-8-beta-carboxamide) is a derivative of LSD. The 1-methyl homologue of LSD is has more of somatic than sensory effect, has fewer visuals and is less well accepted than LSD, with the range of dosages being from 100 to 300 micrograms. This indicates that it is perhaps a third the potency of LSD which is in accord with both pupilary dilation and reflex action. However, the cardiovascular responses are actually increased. Besides being less potent than LSD, it appears to have a slower onset but it is equally long lived. There is cross-tolerance between MLD-41 and LSD.


Template:Pharmacology-stub Template:Hallucinogenic lysergamides

Template:WikiDoc Sources